Physician profile
Sandra Rodriguez
NPI 1164715462
$4,425.47
in general payments reported to CMS, 2019-2025
32 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $165 · 2021: $793 · 2022: $355 · 2023: $777 · 2024: $540 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.96 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.83 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $574.21 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.95 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $307.31 | 2019-2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $276.91 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $234.13 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $228.95 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $202.65 | 2019-2024 | Sutab |
| Celgene Corporation | $149.12 | 2021-2023 | Zeposia |
| Pfizer INC. | $136.49 | 2025 | |
| Medical Device Business Services, INC. | $124.99 | 2021 | |
| Madrigal Pharmaceuticals | $109.66 | 2024-2025 | Rezdiffra, Resmetirom |
| Romark Laboratories, Lc | $104.46 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $94.12 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $79.03 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $75.69 | 2021-2024 | Pentax Medical, C2 Cryoballoon Focal Controller, Inspira |
| Merck Sharp & Dohme LLC | $70.48 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $69.53 | 2024-2025 | Zenpep |
| Dova Pharmaceuticals | $43.22 | 2019 | |
| Nestle Healthcare Nutrition INC. | $39.31 | 2023 | |
| Daiichi Sankyo INC. | $38.58 | 2019-2020 | |
| Novo Nordisk INC | $38.08 | 2023-2025 | Wegovy |
| Evoke Pharma, INC. | $37.92 | 2023-2024 | Gimoti |
| Shire North American Group INC | $34.46 | 2019 | |
| Gilead Sciences, INC. | $26.81 | 2025 | |
| Redhill Biopharma INC. | $24.50 | 2021 | |
| Axonics, INC. | $24.33 | 2023 | Axonics |
| Alfasigma USA, INC. | $24.25 | 2020 | |
| Phathom Pharmaceuticals, INC. | $23.98 | 2025 | Voquezna |
| Exact Sciences Corporation | $23.97 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $22.89 | 2024 | Omvoh |
| Apollo Endosurgery US INC | $16.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.